Evidence map›Paper›PMID 19838129›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2010

Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women.

Stewart E Reid, James Y Dai, Jing Wang, Bupe N Sichalwe, Godspower Akpomiemie, Frances M Cowan, Sinead Delany-Moretlwe, Jared M Baeten, James P Hughes, Anna Wald and 1 more

Registry-linked trialAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00076232 (A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir for the Reduction of HIV Acquisition Among High-Risk HSV-2 Seropositive, HIV Seronegative Individuals), which is not on this map. Cited by 62 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 6 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00076232 phase3completednot on this map

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir for the Reduction of HIV Acquisition Among High-Risk HSV-2 Seropositive, HIV Seronegative Individuals

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2005 to 2007Enrolled3,682ConditionsHIV Infections, HIV Seronegativity, Herpes GenitalisArmsAcyclovir, Acyclovir placebo
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 6 syntheses or guidelines pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

Stewart E ReidHIV Prevention Research, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia. stewart.reid@cidrz.org
James Y Dai
Jing Wang
Bupe N Sichalwe
Godspower Akpomiemie
Frances M Cowan
Sinead Delany-Moretlwe
Jared M Baeten
James P Hughes
Anna Wald
Connie Celum
University of Washington · USCentre for Infectious Disease Research in Zambia · ZMFred Hutch Cancer Center · USUniversity of the Witwatersrand · ZAThe Royal Free Hospital · GBUniversity of Alabama at Birmingham · US

Funding

HIV PREVENTION TRIALS NETWORK LEADERSHIP GROUPU01AI046749 · NIAID · FAMILY HEALTH INTERNATIONAL · PI CATES, WILLARD · 1999 to 2005
$73.5M
Acyclovir to Prevent HIV Acquisition in HSV-2+ PersonsU01AI052054 · NIAID · UNIVERSITY OF WASHINGTON · PI CELUM, CONNIE L · 2005 to 2007
$13.6M
NIAID NIH HHS U01 AI046749NIAID NIH HHS U01 AI052054NIAID NIH HHS U01 AI46749NIAID NIH HHS U01 AI52054
6 · The paper itself

Abstract

backgroundBiomedical HIV prevention trials enroll sexually active women at risk of HIV and often discontinue study product during pregnancy. We assessed risk factors for pregnancy and HIV acquisition, and the effect of pregnancy on time off study drug in HIV Prevention Trials Network 039.

methodsA total of 1358 HIV negative, herpes simplex virus type 2-seropositive women from South Africa, Zambia, and Zimbabwe were enrolled and followed for up to 18 months.

resultsA total of 228 pregnancies occurred; time off study drug due to pregnancy accounted for 4% of woman-years of follow-up among women. Being pregnant was not associated with increased HIV risk (hazard ratio 0.64, 95% confidence interval 0.23-1.80, P = 0.40). However, younger age was associated with increased risk for both pregnancy and HIV. There was no association between condom use as a sole contraceptive and reduced pregnancy incidence; hormonal contraception was not associated with increased HIV risk. Bacterial vaginosis at study entry was associated with increased HIV risk (hazard ratio 2.03, P = 0.02).

conclusionsPregnancy resulted in only a small amount of woman-time off study drug. Young women are at high risk for HIV and are an appropriate population for HIV prevention trials but also have higher risk of pregnancy. Condom use was not associated with reduced incidence of pregnancy.

Indexed as

AdultAfrica South of the SaharaContraceptionFemaleHIVHIV InfectionsHumansIncidencePregnancyPregnancy Complications, InfectiousProportional Hazards ModelsRisk FactorsYoung Adult

Identifiers

PMID19838129
PMCPMC2845724
OpenAlexW1964519673

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.